FDA drug safety meeting
Executive Summary
FDA's pre- and post-marketing safety programs for drugs and biologics will be discussed by the agency's Science Board at an April 15 meeting. Good manufacturing practices for vaccines, blood and cell, tissue and gene products will also be considered. The meeting will be held at the CDER advisory committee conference room beginning at 8:30 a.m...